Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 19/20 | 0.61 |
| ▸ | MMP13 | P45452 | 16/20 | 0.53 |
| ▸ | MMP1 | P03956 | 15/20 | 0.53 |
| ▸ | MMP9 | P14780 | 13/20 | 0.53 |
| ▸ | MMP14 | P50281 | 2/20 | 0.53 |
| ▸ | MMP2 | P08253 | 2/20 | 0.53 |
| ▸ | MMP7 | P09237 | 2/20 | 0.47 |
| ▸ | MMP8 | P22894 | 2/20 | 0.47 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6559410 | 0.90 | ADAM17 (0.51) | ADAM17MMP13MMP1MMP9MMP14 | |
| SCHEMBL6559764 | 0.90 | ADAM17 (0.51) | ADAM17MMP13MMP1MMP9MMP14 | |
| SCHEMBL6558782 | 0.83 | ADAM17 (0.67) | ADAM17MMP13MMP1MMP9 | |
| SCHEMBL6559605 | 0.75 | LMNA (0.52) | ADAM17MMP13MMP1MMP9 | |
| SCHEMBL6559431 | 0.75 | ADAM17 (0.54) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL6559742 | 0.74 | ADAM17 (0.53) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL3941442 | 0.70 | ADAM17 (1.00) | ADAM17MMP13MMP1MMP9MMP14 | |
| SCHEMBL3940130 | 0.70 | MMP13 (0.58) | ADAM17MMP13MMP1MMP9 | |
| SCHEMBL4078599 | 0.69 | ADAM17 (0.58) | ADAM17MMP13MMP1MMP9MMP14 | |
| SCHEMBL4087256 | 0.68 | ADAM17 (0.57) | ADAM17MMP13MMP1MMP9MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1147102-B1 | HETEROARYL ACETYLENIC SULFONAMIDE AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS | WYETH CORP (US) | 2004-03-17 | — | — | EP | claimed |
| US-20020188132-A1 | Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors | WYETH HOLDINGS CORPORATION | 2002-12-12 | — | — | US | claimed |
| EP-1147102-A2 | HETEROARYL ACETYLENIC SULFONAMIDE AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS | American Cyanamid Company (US) | 2001-10-24 | — | — | EP | claimed |
| US-6200996-B1 | ARTHRITIS; BONE, GASTROINTESTINAL DISORDERS; CROHN*S DISEASE, MULTIPLE SCLEROSIS | AMERICAN CYANAMID COMPANY | 2001-03-13 | — | — | US | claimed |
| WO-2000044740-A2 | HETEROARYL ACETYLENIC SULFONAMIDE AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | claimed |
| US-7488754-B2 | Method for the treatment of polycystic kidney disease | WYETH (US) | 2009-02-10 | — | — | US | disclosed |
| US-20040063672-A1 | Method for the treatment of polycystic kidney disease | WYETH HOLDINGS CORPORATION | 2004-04-01 | — | — | US | disclosed |
| EP-1147102-B1 | HETEROARYL ACETYLENIC SULFONAMIDE AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS | WYETH CORP (US) | 2004-03-17 | — | — | EP | disclosed |
| US-20020188132-A1 | Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors | WYETH HOLDINGS CORPORATION | 2002-12-12 | — | — | US | disclosed |
| EP-1147102-A2 | HETEROARYL ACETYLENIC SULFONAMIDE AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS | American Cyanamid Company (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6200996-B1 | ARTHRITIS; BONE, GASTROINTESTINAL DISORDERS; CROHN*S DISEASE, MULTIPLE SCLEROSIS | AMERICAN CYANAMID COMPANY | 2001-03-13 | — | — | US | disclosed |
| WO-2000044740-A2 | HETEROARYL ACETYLENIC SULFONAMIDE AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063672-A1 | Method for the treatment of polycystic kidney disease | PKD1, PKD2, PCSK6 | ADAM17 9/4885MMP13 246/4885MMP1 215/4885 |
| US-20020188132-A1 | Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors | TNF, SI, MMP12 | ADAM17 74/4885MMP13 84/4885MMP1 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.